Morgan Stanley lowered the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $166 from $183 and keeps an Overweight rating on the shares after the company reported Q1 results, including updating its expense guidance to reflect the recent Xyrem antitrust settlement and Chimerix acquisition. Retention of 2025 revenue guidance despite the weaker quarter “should provide some price support,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Optimistic Growth Outlook for Jazz Pharmaceuticals Amid Strategic Product Focus and Pipeline Catalysts
- Positive Outlook for Jazz Pharmaceuticals: Buy Rating Affirmed Amid Strategic Moves and Upcoming Catalysts
- Jazz Pharmaceuticals: Buy Rating Affirmed Amid Growth Potential and Transformative Catalysts
- Jazz Pharmaceuticals Reports Q1 2025 Financial Results
- Optimistic Buy Rating for Jazz Pharmaceuticals Amid Growth Prospects and Strategic Positioning